Wind94Rain

[Wind94Rain @Wind94Rain]

Use of trastuzumab-deruxtecan in women with gynaecological malignancies
https://t.co/5ZuiCqVAX2

[Wind94Rain @Wind94Rain]

Sacituzumab Tirumotecan in an Advanced HR+/HER2-Breast Cancer Patient with Bone Marrow Metastasis-Induced Refractory Thrombocytopenia: A Case Report and Literature Review
https://t.co/rCms7cI0yw

[Wind94Rain @Wind94Rain]

Genomic biomarkers of primary resistance to anti-EGFR monoclonal antibodies (mAbs) by comprehensive genomic profiling (CGP) in EGFR -amplified (ampl) advanced gastroesophageal adenocarcinoma (aGEA) and correlative analysis

https://t.co/gE2vONVkvL

[Wind94Rain @Wind94Rain]

Extrapulmonary small cell carcinoma treated with conventional or tumor-targeted topoisomerase I inhibition plus ATR blockade: Clinical outcomes and molecular correlates.

https://t.co/BrVm7Sbfoq

[Wind94Rain @Wind94Rain]

A phase II evaluation of sacituzumab govitecan in platinum-resistant ovarian cancer (NCT06028932).

https://t.co/M2OlRWRTEE

[Wind94Rain @Wind94Rain]

Development of payload-resistant human ovarian cancer cell lines to better understand antibody-drug conjugate sequencing and resistance mechanisms.

https://t.co/izg9VicX23

[Wind94Rain @Wind94Rain]

Final results and preliminary correlative analysis of a phase I study of anetumab ravtansine in combination with checkpoint inhibitors and gemcitabine in mesothelin-positive advanced pancreatic adenocarcinoma (NCI10208).

https://t.co/wdqNKFNH9e

[Wind94Rain @Wind94Rain]

SHR-A2102, a Nectin-4 targeted antibody-drug conjugate, combined with HRS-4642 in previously treated pancreatic ductal adenocarcinoma harboring KRAS G12D mutation.

https://t.co/H3npX8FagL

[Wind94Rain @Wind94Rain]

SYS6010(EGFR TOP1 ADC) combined with SYH2051(ATR) in advanced solid tumors: Results from a phase Ib/II trial.

https://t.co/TznFLk5Fw7

[Wind94Rain @Wind94Rain]

SHR-A1811 plus chemotherapy and BP102 as 1L therapy for HER2-expressing mCRC: Data from a phase Ib/II study.

https://t.co/8zqtuU5zHg

[Wind94Rain @Wind94Rain]

Phase 1/2 study of CLIO-8221, a HER2-targeted, dual-payload exatecan and ATR inhibitor antibody-drug conjugate (ADC) in patients with advanced HER2-expressing solid tumors.

https://t.co/uakIhuwWBZ

[Wind94Rain @Wind94Rain]

A phase II study of trastuzumab emtansine (T-DM1) combined with ribociclib in patients with HER2-positive metastatic breast cancer (RibHER).

https://t.co/nF8CbOpU10

[Wind94Rain @Wind94Rain]

Real-world outcomes and tumor gene expression analysis of sacituzumab govitecan (SG)- and trastuzumab deruxtecan (T-DXd)-treated metastatic breast cancer (MBC).

https://t.co/OamZ5HJb1G

[LUNGevity Foundation @LUNGevity]

ADC opens door to PARPi combo. Dr. Elizabeth Lee @DanaFarberNews shared data in phase 1 study of T-Dxd & PARP-inhib in #HER2+ ovarian & endometrial cancers. This combo tx may avoid toxicities of PARP + chemo combos, due to #ADC specificity. #AACR26 Additnal studies planned.

[Jordyn Silverstein, MD @JordynSilvs]

Honored to present our teams research @SGO_org in Puerto Rico
1. Claudin-6, an ADC target, is expressed in 50% of ovarian cancers!! With little overlap with folate receptor and HER2

2. MIRV resistance mechanisms- possibly through JAK1 VEGFR2 and MAPK mutations- exploratory but we need more data to understand MIRV resistance

Incredibly grateful to my mentors Dr Konecny, @dradityabardia , Dr Slamon and many more!

[Wind94Rain @Wind94Rain]

Outcomes with subsequent therapies post-enfortumab vedotin/pembrolizumab (EVP) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of the UNITE study.
https://t.co/fOW8RDwEHE

[Wind94Rain @Wind94Rain]

Impact of prior immune checkpoint inhibitor (ICI) and interval from ICI exposure on outcomes with enfortumab vedotin and pembrolizumab (EVP) in advanced urothelial carcinoma (aUC).
https://t.co/EEg28CU2nA

[Wind94Rain @Wind94Rain]

Impact of prior immune checkpoint inhibitor on trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory analysis of the EN-DEAVOR study
https://t.co/MXCZNXqlZ6

[Wind94Rain @Wind94Rain]

Capivasertib Combines with Trastuzumab Deruxtecan to Enhance Antitumor Activity in HER2-Positive and HER2-Low Tumors
https://t.co/XfEHs1o3aQ

[Wind94Rain @Wind94Rain]

Rational payload selection enables high antitumoral efficacy of an anti-EGFR antibody-drug conjugate against ovarian tumors
https://t.co/gbQMulBvXJ